Abstract 12135: Quality of Life in Early-Stage Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial
Catherine G. Ireland(Brigham and Women's Hospital), Carolyn Y. Ho(Brigham and Women's Hospital), Anna Axelsson Raja(Copenhagen University Hospital), Ivan Wilmot(Cincinnati Children's Hospital Medical Center), Joseph W. Rossano(Children's Hospital of Philadelphia), Alexandre C. Pereira(University of Washington), E. John Orav(Mass General Brigham), Anjali Owens(University of Pennsylvania), Jonathan H. Soslow(Vanderbilt University Medical Center), Patel R Amit(University of Chicago), Henning Bundgaard, Matthew T. Wheeler(Stanford University), Kenneth Zahka(Cleveland Clinic), Jason R. Becker(Vanderbilt University), Matthew R.G. Taylor(University of Colorado Anschutz Medical Campus), Luisa Mestroni(University of Colorado Anschutz Medical Campus), Sharlene M. Day(Cardiovascular Institute of the South), Richard G. Bach(Washington University in St. Louis), Mark W. Russell(University of Michigan), Charles E. Canter
Cited by 0
Related Papers
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands
|Nature Genetics|2017|927